Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells

Oncotarget

Volumn 8, Issue 25, 2017, Pages 40318-40326

  Chen, Jian ^a,b   Mu, Qitian ^a,b,c   Li, Xia ^a,b   Yin, Xiufeng ^a,b   Yu, Mengxia ^a,b   Jin, Jing ^a,b   Li, Chenying ^a,b   Zhou, Yile ^a,b   Zhou, Jiani ^a,b,d   Suo, Shanshan ^a,b   Lu, Demin ^a,b   Jin, Jie ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c NINGBO FIRST HOSPITAL   (China)

^d Lihuili Hospital of Ningbo Medical Center   (China)

Author keywords

Acute myeloid leukemia; Homoharringtonine; Smad3; TGF

Indexed keywords

HOMOHARRINGTONINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SERINE; SHORT HAIRPIN RNA; SMAD3 PROTEIN; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; HARRINGTONINE DERIVATIVE; SMAD3 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ACUTE MYELOID LEUKEMIA; ACUTE MYELOID LEUKEMIA CELL LINE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MTT ASSAY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SOFTWARE; WESTERN BLOTTING; DRUG EFFECT; GENETICS; METABOLISM; PHOSPHORYLATION; RNA INTERFERENCE; THP-1 CELL LINE; TUMOR CELL LINE; U-937 CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINTS; HARRINGTONINES; HOMOHARRINGTONINE; HUMANS; LEUKEMIA, MYELOID, ACUTE; PHOSPHORYLATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SMAD3 PROTEIN; THP-1 CELLS; TRANSFORMING GROWTH FACTOR BETA; U937 CELLS;

EID: 85020951744     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16956     Document Type: Article

References (30)

1. Powell RG, Weisleder D, Smith CR Jr. Antitumor alkaloids for Cephalataxus harringtonia: structure and activity. J Pharm Sci. 1972; 61:1227-30
2. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J (Engl). 1976; 2:263-72
3. Harringtonine in acute leukemias. Clinical analysis of 31 cases. Chin Med J (Engl). 1977; 3:319-24
4. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchison JL, et al. Treatment of Acute Myelocytic-Leukemia-a Study by Cancer and Leukemia Group-B. Blood. 1981; 58:1203-12
5. Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, Cook P, Baskind P. Homoharringtonine Is Safe and Effective for Patients with Acute Myelogenous Leukemia. Leukemia. 1992; 6:1185-8
6. Maiti A, Cortes J, Ferrajoli A, Estrov Z, Borthakur G, Garcia-Manero G, Jabbour E, Ravandi F, O'Brien S, Kantarjian H. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia. Leuk Lymphoma. 2017:1-6. doi: 10.1080/10428194.2017.1283030
7. Gu LF, Zhang WG, Wang FX, Cao XM, Chen YX, He AL, Liu J, Ma XR. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. J Cancer Res Clin Oncol. 2011; 137:997-1003. doi: 10.1007/s00432-010-0947-z
8. Levy V, Zohar S, Bardin C, VekhoffA, Chaoui D, Rio B, Legrand O, Sentenac S, Rousselot P, Raffoux E, Chast F, Chevret S, Marie JP. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer. 2006; 95:253-9
9. Jin J, Jiang DZ, Mai WY, Meng HT, Qian WB, Tong HY, Huang J, Mao LP, Tong Y, Wang L, Chen ZM, Xu WL. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia. 2006; 20:1361-7
10. Feldman E, Arlin Z, Ahmed T, Mittelman A, Puccio C, Chun H, Cook P, Baskind P. Homoharringtonine in Combination with Cytarabine for Patients with Acute Myelogenous Leukemia. Leukemia. 1992; 6:1189-91
11. Li X, Yin X, Wang H, Huang J, Yu M, Ma Z, Li C, Zhou Y, Yan X, Huang S, Jin J. The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia. Oncotarget. 2017; 8:12764-12774. doi: 10.18632/oncotarget.14463
12. Yinjun L, Jie J, Weilai X, Xiangming T. Homoharringtonine mediates myeloid cell apoptosis via upregulation of proapoptotic bax and inducing caspase-3-mediated cleavage of poly (ADP-ribose) polymerase (PARP). Am J Hematol. 2004; 76:199-204. doi: 10.1002/ajh.20100
13. Wang L, You LS, Ni WM, Ma QL, Tong Y, Mao LP, Qian JJ, Jin J. beta-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia. Leuk Res. 2013; 37:1329-40. doi: 10.1016/j.leukres.2013.06.023
14. Fresno M, Jimenez A, Vazquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem. 1977; 72:323-30
15. Gu Y, Chen T, Meng Z, Gan Y, Xu X, Lou G, Li H, Gan X, Zhou H, Tang J, Xu G, Huang L, Zhang X, et al. CaMKII gamma, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine. Blood. 2012; 120:4829-39. doi: 10.1182/blood-2012-06-434894
16. Zhang T, Shen S, Zhu Z, Lu S, Yin X, Zheng J, Jin J. Homoharringtonine binds to and increases myosin-9 in myeloid leukemia. Br J Pharmacol. 2015; 173:212-21. doi: 10.1111/bph.13359
17. Jin J, Wang JX, Chen FF, Wu DP, Hu J, Zhou JF, Hu JD, Wang JM, Li JY, Huang XJ, Ma J, Ji CY, Xu XP, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, openlabel, randomised, controlled phase 3 trial. Lancet Oncol. 2013; 14:599-608. doi: 10.1016/s1470-2045(13)70152-9
18. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson L, Hester J, Rios M, AndreeffM, Talpaz M. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995; 86:3322-6
19. Quintas-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res. 2008; 14:4392-9. doi: 10.1158/1078-0432.ccr-08-0117
20. Legros L, Hayette S, Nicolini FE, Raynaud S, Chabane K, Magaud JP, Cassuto JP, Michallet M. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia. 2007; 21:2204-6. doi: 10.1038/sj.leu.2404772
21. Chen Y, Hu Y, Michallet S. Inhibitory effects of hommoharringtonine on leukemic stem cells and BCR-ABL induced chornic myeloid leukemia and acute lymphoblastic leukemia in mice [abstract]. Blood (ASH Annual Meeting Abstract). 2007; 110:2912
22. Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S, Gajewski A, Murgo A, Cheson B, O'Brien S. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000; 18:3513-21
23. Kuroda J, Kamitsuji Y, Kimura S, Ashihara E, Kawata E, Nakagawa Y, Takeuichi M, Murotani Y, Yokota A, Tanaka R, AndreeffM, Taniwaki M, Maekawa T. Antimyeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. Int J Hematol. 2008; 87:507-15. doi: 10.1007/s12185-008-0081-8
24. Tong H, Ren Y, Zhang F, Jin J. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells. Eur J Haematol. 2008; 81:259-66. doi: 10.1111/j.1600-0609.2008.01116.x
25. Westermaier Y, Barril X, Scapozza L. Virtual screening: an in silico tool for interlacing the chemical universe with the proteome. Methods. 2015; 71:44-57. doi: 10.1016/j. ymeth.2014.08.001
26. Chen YC. Beware of docking! Trends Pharmacol Sci. 2014; 36:78-95. doi: 10.1016/j.tips.2014.12.001
27. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C, Grippo PJ. TGF-beta: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 2014; 106:djt369. doi: 10.1093/jnci/djt369
28. Wakefield LM, Hill CS. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat Rev Cancer. 2013; 13:328-41. doi: 10.1038/nrc3500
29. Massague J. TGF beta signalling in context. Nat Rev Mol Cell Bio. 2012; 13:616-30. doi: 10.1038/nrm3434
30. Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016; 529:298-306. doi: 10.1038/nature17038